<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(8)</volume><submitter>Arredondo Montero J</submitter><pubmed_abstract>&lt;b>Introduction:&lt;/b> Leucine-rich alpha-2-glycoprotein 1(LRG-1) is a human protein that has shown potential usefulness as a biomarker for diagnosing pediatric acute appendicitis (PAA). This study aims to validate the diagnostic performance of serum LRG-1 in PAA. &lt;b>Material and Methods:&lt;/b> This work is a subgroup analysis from BIDIAP (BIomarkers for DIagnosing Appendicitis in Pediatrics), a prospective single-center observational cohort, to validate serum LRG-1 as a diagnostic tool in PAA. This analysis included 200 patients, divided into three groups: (1) healthy patients undergoing major outpatient surgery (&lt;i>n&lt;/i> = 56), (2) patients with non-surgical abdominal pain (&lt;i>n&lt;/i> = 52), and (3) patients with a confirmed diagnosis of PAA (&lt;i>n&lt;/i> = 92). Patients in group 3 were divided into complicated and uncomplicated PAA. In all patients, a serum sample was obtained during recruitment, and LRG-1 concentration was determined by Enzyme-Linked ImmunoSorbent Assay (ELISA). Comparative statistical analyses were performed using the Mann-Whitney U, Kruskal-Wallis, and Fisher's exact tests. The area under the receiver operating characteristic curves (AUC) was calculated for all pertinent analyses. &lt;b>Results:&lt;/b> Serum LRG-1 values, expressed as median (interquartile range) were 23,145 (18,246-27,453) ng/mL in group 1, 27,655 (21,151-38,795) ng/mL in group 2 and 40,409 (32,631-53,655) ng/mL in group 3 (&lt;i>p&lt;/i> &lt; 0.0001). Concerning the type of appendicitis, the serum LRG-1 values obtained were 38,686 (31,804-48,816) ng/mL in the uncomplicated PAA group and 51,857 (34,013-64,202) ng/mL in the complicated PAA group (&lt;i>p&lt;/i> = 0.02). The area under the curve (AUC) obtained (group 2 vs. 3) was 0.75 (95% CI 0.67-0.84). For the discrimination between complicated and uncomplicated PAA, the AUC obtained was 0.66 (95% CI 0.52-0.79). &lt;b>Conclusions:&lt;/b> This work establishes normative health ranges for serum LRG-1 values in the pediatric population and shows that serum LRG-1 could be a potentially helpful tool for diagnosing PAA in the future. Future prospective multicenter studies, with the parallel evaluation of urinary and salivary LRG-1, are necessary to assess the implementability of this molecule in actual clinical practice.</pubmed_abstract><journal>Biomedicines</journal><pagination>1821</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11352011</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Diagnostic Performance of Serum Leucine-Rich Alpha-2-Glycoprotein 1 in Pediatric Acute Appendicitis: A Prospective Validation Study.</pubmed_title><pmcid>PMC11352011</pmcid><pubmed_authors>Fernandez-Celis A</pubmed_authors><pubmed_authors>Lopez-Andres N</pubmed_authors><pubmed_authors>Ros Briones R</pubmed_authors><pubmed_authors>Martin-Calvo N</pubmed_authors><pubmed_authors>Arredondo Montero J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Diagnostic Performance of Serum Leucine-Rich Alpha-2-Glycoprotein 1 in Pediatric Acute Appendicitis: A Prospective Validation Study.</name><description>&lt;b>Introduction:&lt;/b> Leucine-rich alpha-2-glycoprotein 1(LRG-1) is a human protein that has shown potential usefulness as a biomarker for diagnosing pediatric acute appendicitis (PAA). This study aims to validate the diagnostic performance of serum LRG-1 in PAA. &lt;b>Material and Methods:&lt;/b> This work is a subgroup analysis from BIDIAP (BIomarkers for DIagnosing Appendicitis in Pediatrics), a prospective single-center observational cohort, to validate serum LRG-1 as a diagnostic tool in PAA. This analysis included 200 patients, divided into three groups: (1) healthy patients undergoing major outpatient surgery (&lt;i>n&lt;/i> = 56), (2) patients with non-surgical abdominal pain (&lt;i>n&lt;/i> = 52), and (3) patients with a confirmed diagnosis of PAA (&lt;i>n&lt;/i> = 92). Patients in group 3 were divided into complicated and uncomplicated PAA. In all patients, a serum sample was obtained during recruitment, and LRG-1 concentration was determined by Enzyme-Linked ImmunoSorbent Assay (ELISA). Comparative statistical analyses were performed using the Mann-Whitney U, Kruskal-Wallis, and Fisher's exact tests. The area under the receiver operating characteristic curves (AUC) was calculated for all pertinent analyses. &lt;b>Results:&lt;/b> Serum LRG-1 values, expressed as median (interquartile range) were 23,145 (18,246-27,453) ng/mL in group 1, 27,655 (21,151-38,795) ng/mL in group 2 and 40,409 (32,631-53,655) ng/mL in group 3 (&lt;i>p&lt;/i> &lt; 0.0001). Concerning the type of appendicitis, the serum LRG-1 values obtained were 38,686 (31,804-48,816) ng/mL in the uncomplicated PAA group and 51,857 (34,013-64,202) ng/mL in the complicated PAA group (&lt;i>p&lt;/i> = 0.02). The area under the curve (AUC) obtained (group 2 vs. 3) was 0.75 (95% CI 0.67-0.84). For the discrimination between complicated and uncomplicated PAA, the AUC obtained was 0.66 (95% CI 0.52-0.79). &lt;b>Conclusions:&lt;/b> This work establishes normative health ranges for serum LRG-1 values in the pediatric population and shows that serum LRG-1 could be a potentially helpful tool for diagnosing PAA in the future. Future prospective multicenter studies, with the parallel evaluation of urinary and salivary LRG-1, are necessary to assess the implementability of this molecule in actual clinical practice.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Aug</publication><modification>2025-04-05T12:29:31.33Z</modification><creation>2025-04-05T12:29:31.33Z</creation></dates><accession>S-EPMC11352011</accession><cross_references><pubmed>39200285</pubmed><doi>10.3390/biomedicines12081821</doi></cross_references></HashMap>